德国南部和拉脱维亚TBE疫苗接种有效性研究
该生态学研究利用2007至2018年拉脱维亚和德国南部(巴伐利亚州和巴登-符腾堡州)公共卫生机构报告的TBE病例及疫苗接种史数据,结合全国代表性调查估计的接种率,按年龄组、接种史和接种程序依从性评估TBE疫苗有效性(VE)。结果显示,按程序接种2剂、3剂和≥4剂后,两地各年龄组VE均很高;即使超过预定接种时间,VE仍维持较高水平。作者认为,为获得可持续的长期保护,可考虑采用更长、更灵活的加强剂间隔。
要点
- 按程序接种2剂、3剂和≥4剂后,德国南部VE分别为97.2%、95.0%和95.4%,拉脱维亚分别为98.1%、99.4%和98.8%。
- 超出预定接种时间后,德国南部VE分别为90.6%、89.9%和95.6%,拉脱维亚分别为97.4%、98.4%和99.0%。
- 作者认为,为获得可持续长期保护,可考虑采用更长、更灵活的加强剂间隔。
核心结论
- 在拉脱维亚和德国南部,按程序接种2剂和3剂基础免疫后,各年龄组VE均很高。
- 接种加强剂后,即使距上次接种时间延长,仍观察到高VE,提示可考虑采用更长、更灵活的加强剂间隔以获得可持续长期保护。
研究设计与样本
- 生态学研究,评估2007年至2018年拉脱维亚和德国南部各州TBE疫苗有效性。
- TBE病例和接种史来自拉脱维亚及德国南部巴伐利亚州和巴登-符腾堡州公共卫生机构。
- 按年龄组、接种史和接种程序依从性分析;接种率通过代表性全国调查估计。
- 病例在下一预定剂次前的时间间隔内诊断为“按程序”,在下一预定剂次后诊断为“超出程序”。
主要发现
- 按程序接种2剂、3剂和≥4剂后,德国南部VE分别为97.2%、95.0%和95.4%,拉脱维亚分别为98.1%、99.4%和98.8%。
- 超出程序接种后,德国南部VE分别为90.6%、89.9%和95.6%,拉脱维亚分别为97.4%、98.4%和99.0%,各年龄组间仅见微小差异。
临床怎么用
- 作者认为,为获得可持续的长期保护,可考虑采用更长、更灵活的加强剂间隔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tick-borne encephalitis (TBE) is a vaccine-preventable disease which may cause long-term sequelae and even death. The data on the long-term effectiveness of TBE vaccines are limited. Additionally, the vaccination schedule is complex which in part contributes towards sub-optimal uptake in TBE-endemic areas. The current ecological study measures vaccine effectiveness (VE) in two European countries. METHODS: TBE VE was measured from 2007 to 2018 in Latvia and Southern German states by age group, vaccination history, and schedule compliance. TBE cases and vaccination history were obtained from the public health agencies for Latvia and the southern German federal states of Bavaria and Baden-Wuerttemberg. Cases were "within schedule" if a TBE infection was diagnosed within the time interval preceding the next scheduled dose and "outside schedule" if the diagnosis occurred after the next scheduled dose. Vaccine uptake was estimated via representative nationwide surveys. RESULTS: VE after 2, 3, and ≥4 doses was high in both countries at 97.2%, 95.0%, and 95.4% for southern Germany, and 98.1%, 99.4%, and 98.8% for Latvia while within- schedule, and only showed marginal differences outside schedule at 90.6%, 89.9%, and 95.6% for southern Germany, and 97.4%, 98.4%, and 99.0% for Latvia regardless of age groups. CONCLUSIONS: In both countries, VE after two and three primary doses within-schedule was very high in all age groups. Once receiving booster doses, high VE continued to be observed even in persons with extended intervals since the last dose received, suggesting that longer and more flexible booster intervals may be considered for sustainable long-term protection.
引用
- Erber W, Khan F, Zavadska D, et al. Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine. 2021. PMID: 34952753. doi:10.1016/j.vaccine.2021.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。